EFFECT OF TAMOXIFEN ON SERUM-CHOLESTEROL AND LIPOPROTEINS DURING CHEMOHORMONAL THERAPY

被引：39

作者：

DNISTRIAN, AM ^{[1
]}

SCHWARTZ, MK ^{[1
]}

GREENBERG, EJ ^{[1
]}

SMITH, CA ^{[1
]}

SCHWARTZ, DC ^{[1
]}

机构：

[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021

来源：

CLINICA CHIMICA ACTA | 1993年 / 223卷 / 1-2期

关键词：

BREAST CANCER; TAMOXIFEN; SERUM CHOLESTEROL; SERUM LIPOPROTEINS; CARDIOVASCULAR RISK;

D O I：

10.1016/0009-8981(93)90061-8

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

The effect of tamoxifen on serum cholesterol, high density lipoprotein cholesterol (HDL-cholesterol), low density lipoprotein cholesterol (LDL-cholesterol) and the ratio of LDL-cholesterol to HDL-cholesterol (LDL-C/HDL-C) was investigated in breast cancer patients undergoing therapy for advanced disease. Longitudinal studies in 24 patients treated with tamoxifen (10 mg, twice daily) indicated average decreases in total serum cholesterol (17%) and LDL-cholesterol (27%), whereas the effect of tamoxifen on HDL-cholesterol varied with the individual patient. There was a significant decrease in the LDL-C/HDL-C ratio (33%) consistent with a decreased risk for coronary artery disease. This beneficial influence of tamoxifen on risk factors associated with cardiovascular disease was evident in both premenopausal and postmenopausal patients whether tamoxifen was administered alone or in combination with cytotoxic chemotherapy.

引用

页码：43 / 52

页数：10

共 34 条

[1] EFFECTS OF TAMOXIFEN TREATMENT ON PLASMA-LIPIDS AND LIPOPROTEIN LIPID-COMPOSITION [J].

BAGDADE, JD ;

WOLTER, J ;

SUBBAIAH, PV ;

RYAN, W .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :1132-1135

[2]

Barrett-Connor E, 1989, Cardiovasc Clin, V19, P159

[3] ADJUVANT TAMOXIFEN IN PRIMARY BREAST-CANCER - INFLUENCE ON PLASMA-LIPIDS AND ANTITHROMBIN-III LEVELS [J].

BERTELLI, G ;

PRONZATO, P ;

AMOROSO, D ;

CUSIMANO, MP ;

CONTE, PF ;

MONTAGNA, G ;

BERTOLINI, S ;

ROSSO, R .

BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (03) :307-310

[4] TAMOXIFEN, SERUM-LIPOPROTEINS AND CARDIOVASCULAR RISK [J].

BRUNING, PF ;

BONFRER, JMG ;

HART, AAM ;

DEJONGBAKKER, M ;

LINDERS, D ;

VANLOON, J ;

NOOYEN, WJ .

BRITISH JOURNAL OF CANCER, 1988, 58 (04) :497-499

[5] HDL CHOLESTEROL AND OTHER LIPIDS IN CORONARY HEART-DISEASE - COOPERATIVE LIPOPROTEIN PHENOTYPING STUDY [J].

CASTELLI, WP ;

DOYLE, JT ;

GORDON, T ;

HAMES, CG ;

HJORTLAND, MC ;

HULLEY, SB ;

KAGAN, A ;

ZUKEL, WJ .

CIRCULATION, 1977, 55 (05) :767-772

[6]

Dnistrian A. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P245

[7]

DNISTRIAN A M, 1992, Clinical Chemistry, V38, P973

[8]

DNISTRIAN AM, 1985, CANCER, V56, P63, DOI 10.1002/1097-0142(19850701)56:1<63::AID-CNCR2820560111>3.0.CO

[9]

2-7

[10] NEW PERSPECTIVE ON CANCER OF THE CONTRALATERAL BREAST - A MARKER FOR ASSESSING TAMOXIFEN AS A PREVENTIVE AGENT [J].

FISHER, B ;

REDMOND, C .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (18) :1278-1280

← 1 2 3 4 →